US2014364591A1PendingUtilityA1

Psca: prostate stem cell antigen and uses thereof

69
Assignee: UNIV CALIFORNIAPriority: Mar 10, 1997Filed: Jun 5, 2014Published: Dec 11, 2014
Est. expiryMar 10, 2017(expired)· nominal 20-yr term from priority
Inventors:Robert E. ReiterOwen N. WitteDouglas SaffranAya Jakobovits
A61P 35/00A61P 35/04G01N 33/57557G01N 33/57555G01N 33/57525G01N 33/575A61K 51/106C07K 16/30A61K 39/39558C07K 2319/00G01N 33/567A61K 51/1072A61K 45/06C07K 2317/24C07K 16/3069A61K 2039/505A61K 47/6869C07K 2317/77A61K 38/00C07K 2317/734A61K 31/704C07K 2317/73C07K 2317/732C07K 14/4748G01N 33/577A61K 39/395C07K 2317/92A01K 2217/05C07K 2317/34C07K 14/705G01N 33/53C07K 16/3038G01N 2333/705
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Claims

exact text as granted — not AI-modified
1 . An antibody which specifically binds to PSCA on the surface of carcinoma cells, and is internalized within the carcinoma cells to which it binds. 
     
     
         2 - 52 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.